ClinicalTrials.gg
TerminatedNCT00474188Updated Sep 2, 2009Results posted

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of CC-5013 (lenalidomide) and dexamethasone in Diffuse Large B-cell Lymphoma, sponsored by Celgene Corporation. Terminated at 24 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-02.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse — 14 open to participants now, 29 under way, 4 of them phase 3. Lenalidomide · Lymphoma, Large B-Cell, Diffuse.

Enrollment
59th of 70
26 · median 55
Started
2007
the only one that year
Phase 2
32 of 71
11 open now
Registered
2nd of 71
by date

Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, this one is the 59th largest by enrollment of the 70 interventional ones that give a count, is the only one that started in 2007, is one of 32 in phase 2, and was the 2nd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

14 of the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse are open now, in 4 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Read the detailed description

Non-Hodgkin's lymphoma (NHL) can be divided into two general prognostic groups: the indolent lymphomas and the aggressive lymphomas. Indolent lymphomas have a relatively good prognosis, with median survival time as long as 10 years, but they are not usually curable in advanced stages. Aggressive NHL constitutes about half of all cases of NHL in North America and Western Europe. Of the aggressive lymphomas, diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for up to 30 percent of newly diagnosed cases. The aggressive type of NHL has a shorter natural history; approximately 50-60% of these subjects can be cured with combination chemotherapy regimens. Even with recent advances, many patients with advanced stage DLBCL are not cured with conventional therapy. This leaves a subset of subjects who will eventually relapse or who are refractory to treatment.

Due to the variation in the clinical behavior of the different types of aggressive NHL, it is important to test lenalidomide in DLBCL. Other studies are addressing the activity of lenalidomide in the other types of aggressive lymphomas, as well as in indolent NHL. It is important to test lenalidomide in combination therapy. This study is focused on treating subjects with relapsed or refractory DLBCL using oral lenalidomide in combination with oral dexamethasone.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Celgene
  • Revlimid
  • Lenalidomide
  • Diffuse Large B-cell lymphoma
  • Non-Hodgkins lymphoma
  • CC-5013
  • Response Rate
  • Tumor Control Rate
  • Duration of Response
  • Time to Progression
  • Progression-free survival and safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven diffuse large B-cell non-Hodgkin's lymphoma
  • to previous therapy for non-Hodgkin's lymphoma
  • on cross sectional imaging that is at least 2 cm in the longest diameter
  • performance score of 0,1 or 2
  • Willing to follow the pregnancy precautions

Exclusion criteria

Exclusion Criteria:

  • Any of the following laboratory abnormalities.
  • (ANC) \< 1,500 cells/mm3 (1.5 x 109/L).
  • count \< 60,000/mm3 (60 x 109/L).
  • Serum /AST or SGPT/ALT 5.0 x (ULN).
  • Serum total > 2.0 mg/dL (34 µmol/L).
  • Subjects who are candidates for and willing to undergo an stem cell transplant.
  • History of active CNS lymphoma within the previous 3 months
  • Subjects not willing or unable to take DVT prophylaxis
  • History of other within the past year
  • Positive or active or C
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: CC-5013 (lenalidomide) · Drug: dexamethasone

Interventions

  • Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle

    Also known as: CC-5013, lenalidomide, Revlimid

  • Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Tumor Response Rate

    Number of participants demonstrating complete or partial tumor response (Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J, et al, Report of an international workshop to standardize response criteria for non-Hodgkins' lymphoma. J Clin Oncol.1999;17:1244-53). Study terminated prematurely. Analysis not conducted.

    Time frame: One Year

Secondary outcomes

  1. Tumor Control Rate

    Number of participants demonstrating complete tumor response, partial tumor response, or stable disease. Study terminated prematurely. Analysis not conducted.

    Time frame: One Year

  2. Duration of Response

    Time from first demonstration of at least a partial response to the first documentation of disease progression, including death due to non-Hodgkin's lymphoma. Study terminated prematurely. Analysis not conducted.

    Time frame: One year

  3. Time to Progression

    Time from the start of study drug therapy to the first documentation of disease progression. Study terminated prematurely. Analysis not conducted.

    Time frame: One year

  4. Progression-free Survival

    Time from the start of study drug therapy to the first observation of disease progression or death due to any cause. Study terminated prematurely. Analysis not conducted.

    Time frame: One year

07

Results

Posted Aug 13, 2009
Limitations and caveats
Study terminated prematurely as a business decision. Analyses of efficacy not conducted.

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide in Combination With Dexamethasone
Started26
Completed20
Not completed6
Withdrew: Withdrawal by subject1
Withdrew: Study discontinued by sponsor5

Outcome measures

PrimaryTumor Response Rate

Number of participants demonstrating complete or partial tumor response (Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J, et al, Report of an international workshop to standardize response criteria for non-Hodgkins' lymphoma. J Clin Oncol.1999;17:1244-53). Study terminated prematurely. Analysis not conducted.

Time frame:
One Year
Reported as:
Mean · Participants

No measurements were reported for this outcome.

SecondaryTumor Control Rate

Number of participants demonstrating complete tumor response, partial tumor response, or stable disease. Study terminated prematurely. Analysis not conducted.

Time frame:
One Year
Reported as:
Mean · Participants

No measurements were reported for this outcome.

SecondaryDuration of Response

Time from first demonstration of at least a partial response to the first documentation of disease progression, including death due to non-Hodgkin's lymphoma. Study terminated prematurely. Analysis not conducted.

Time frame:
One year
Reported as:
Median · Days

No measurements were reported for this outcome.

SecondaryTime to Progression

Time from the start of study drug therapy to the first documentation of disease progression. Study terminated prematurely. Analysis not conducted.

Time frame:
One year
Reported as:
Median · Days

No measurements were reported for this outcome.

SecondaryProgression-free Survival

Time from the start of study drug therapy to the first observation of disease progression or death due to any cause. Study terminated prematurely. Analysis not conducted.

Time frame:
One year
Reported as:
Median · Days

No measurements were reported for this outcome.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lenalidomide in Combination With Dexamethasone
<=18 years0
Between 18 and 65 years10
>=65 years16
Age Continuous
Age Continuous(years)Lenalidomide in Combination With Dexamethasone
Mean66.7 ± 11.42
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide in Combination With Dexamethasone
Female10
Male16
Region of Enrollment
Region of Enrollment(participants)Lenalidomide in Combination With Dexamethasone
Australia4
Canada2
United States20
08

Study locations

24 sites
  • Palo Verde Hematology/Oncology, Ltd.
    Glendale, Arizona 85304, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Hematology/Oncology Associates of Treasure Coast
    Port St. Lucie, Florida 34952, United States
  • Northwest Georgia Oncology Centers
    Marietta, Georgia 30060, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Arlington Heights, Illinois 60005, United States
  • Northwestern University, Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Southwest Oncology Associates
    Lafayette, Louisiana 70503, United States
  • Washington County Hospital, The Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Kalamazoo Hematology & Oncology
    Kalamazoo, Michigan 49048, United States
  • Oncology & Hematology Specialists, PA
    Denville, New Jersey 07834, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Northwestern Carolina, Oncology and Hematology PA
    Hickory, North Carolina 28602, United States
  • New Bern Cancer Care
    New Bern, North Carolina 28562, United States
  • James Cancer Hospital
    Columbus, Ohio 43210, United States
  • SouthWest Regional Cancer Center
    Austin, Texas 78705, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • The Alfred Hospital
    Melbourne, Victoria VIC3050, Australia
  • Frankston Hospital
    Frankston, VIC 3199, Australia
  • HOCA
    South Brisbane, QLD 4101, Australia
  • Border Medical Oncology
    Wodonga, VIC 3690, Australia
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2007
First posted
May 16, 2007
Start
May 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Aug 13, 2009
Last update
Sep 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00474188
First posted
May 16, 2007
Start date
May 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Aug 13, 2009
Last update
Sep 2, 2009

Study contacts

Andrew Spencer, MD
principal investigator · The Alfred

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion